Wockhardt Hospitals will expand to 10 to 15 hospitals over the next few years
Pharma giant Wockhardt group promoted Wockhardt Hospital will invest Rs 500 crore (Rs 5 billion) in four Greenfield projects in the next three-year for its ultra super speciality clinics to be built in Mumbai, Delhi, Bangalore, and Kolkata.
Pharmaceutical major Wockhardt Ltd on Saturday claimed it has developed a new form of long-lasting insulin called Glargin and plans to launch it in India by 2006.
The 11-member Indian Pharmaceutical Alliance has frozen the prices of all decontrolled medicines until March 31, 2005, in view of high inflation.
Wockhardt Hospitals, a leading speciality hospital chain, on Saturday announced its plans to open two hospitals in Hyderabad.
Pharmaceutical and biotechnology major Wockhardt on Monday said it would invest Rs 50 crore (Rs 500 million) for setting up a research and development centre in Aurangabad.
As part of its major expansion plans overseas, pharma major Wockhardt Ltd has set up joint ventures in Mexico and South Africa and established a wholly-owned subsidiary in Brazil.
Pharma-major Wockhardt Ltd has set up a sales and marketing subsidiary in the United States to drive its business in the world's largest pharmaceutical market.
The Mulund complex, which already has a heart hospital, would also have speciality unit on bone and joint, Wockhardt chairman Habil Khorakiwala told reporters in Mumbai.
Pharma major Wockhardt said on Thursday that it had achieved a breakthrough in the development of Glargine, a new generation advanced insulin
Pharma major Wockhardt is looking to acquire a German firm this year to strengthen its position in Europe and has set an overall sales target of Rs 100 crore (Rs 1 billion) from its biotech products for this year.
Drugmaker major Wockhardt plans to introduce two new products - recombinant Human Insulin and Interferon alpha 2b - in the domestic market next year.
Pharma major Wockhardt Ltd's consolidated net profit increased 35.6 per cent to Rs 142.5 crore (Rs 1.42 billion) for financial year ended December 2003
The Wockhardt Group plans to invest Rs 400-500 crore to establish new super speciality hospitals in Delhi, Mumbai, Kolkata and Bangalore in the next three years, a top official of the group said on Saturday.
The FDA had imposed a ban on the company's Waluj plant in May.
The former McKinsey India head is presently on board of many big Indian conglomerates.
Company is among the few companies in the sector getting pulled up by FDA for violations at its factories in India.
Airtel acquired African telecom operator Zain in 2010 for $10.7 billion.
Its Waluj manufacturing facility in Maharashtra failed to meet the good manufacturing norms prescribed by the UK drug regulator.
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
As record stock market rally continues, the value of shares directly owned by next-generation business leaders at 20 major corporate houses has soared over 18 per cent to Rs 17,000 crore.
Ranbaxy, which is 63.5 per cent-owned by Japan's Daiichi Sankyo Co and gets more than 40 per cent of its sales from the United States, did not immediately respond to a request on Wednesday for comment on the FDA observations.
The Goqii fitness tracker is a wrist band that measures one's steps, calories burnt, distance travelled, and even tracks the sleeping patterns.
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances